Survival times in months for two groups - YOUR NAME 1 Two groups of chronic hepatitis patients 04:50 Tuesday, September 27, 2005 The data as SAS sees it: Obs group zz status months 1 Prednisone Prednisone -1 . 2 Prednisone 2 0 2 3 Prednisone 6 0 6 4 Prednisone 12 0 12 5 Prednisone 54 0 54 6 Prednisone 56 1 56 7 Prednisone 68 0 68 8 Prednisone 89 0 89 9 Prednisone 96 0 96 10 Prednisone 96 0 96 11 Prednisone 125 1 125 12 Prednisone 128 1 128 13 Prednisone 131 1 131 14 Prednisone 140 1 140 15 Prednisone 141 1 141 16 Prednisone 143 0 143 17 Prednisone 145 1 145 18 Prednisone 146 0 146 19 Prednisone 148 1 148 20 Prednisone 162 1 162 21 Prednisone 168 0 168 22 Prednisone 173 1 173 23 Prednisone 181 1 181 24 Control Control -1 . 25 Control 2 0 2 26 Control 3 0 3 27 Control 4 0 4 28 Control 7 0 7 29 Control 10 0 10 30 Control 22 0 22 31 Control 28 0 28 32 Control 29 0 29 33 Control 32 0 32 34 Control 37 0 37 35 Control 40 0 40 36 Control 41 0 41 37 Control 54 0 54 38 Control 61 0 61 39 Control 63 0 63 40 Control 71 0 71 41 Control 127 1 127 42 Control 140 1 140 43 Control 146 1 146 44 Control 158 1 158 45 Control 167 1 167 46 Control 182 1 182 Survival times in months for two groups - YOUR NAME 2 Two groups of chronic hepatitis patients 04:50 Tuesday, September 27, 2005 Proc lifetest plots and tests The LIFETEST Procedure Summary of the Number of Censored and Uncensored Values Percent Stratum group Total Failed Censored Censored 1 Control 22 16 6 27.27 2 Prednisone 22 11 11 50.00 ----------------------------------------------------------------- Total 44 27 17 38.64 NOTE: There were 2 observations with missing values, negative time values or frequency values less than 1. Survival times in months for two groups - YOUR NAME 3 Two groups of chronic hepatitis patients 04:50 Tuesday, September 27, 2005 Proc lifetest plots and tests The LIFETEST Procedure Survival Function Estimates SDF | | | | | | 1.0 + ** | | S | *P u | CP-P r | | | v | CC P-----------P i | CC P---P v 0.8 + | | a | C---C P------P l | | | | CC P-P D | CC | i | | | s | CC P-------------P t 0.6 + CC | r | | | i | CC PP b | C | u | | | t | C---C P-----P i | | | o 0.4 + C-C | n | CC | | | | F | C-C P u | C n | c | t 0.2 + i | o | n | | | | 0.0 + | | | | | ----+-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+---- 0 20 40 60 80 100 120 140 160 180 200 months Survival times in months for two groups - YOUR NAME 4 Two groups of chronic hepatitis patients 04:50 Tuesday, September 27, 2005 Proc lifetest plots and tests The LIFETEST Procedure Censored Observations Strata P + P PPP *PP P P P C + C C C C C C -----+----+----+----+----+----+----+----+----+----+----+----- 0 20 40 60 80 100 120 140 160 180 200 months Legend for Strata Stratum Symbol group 1 C Control 2 P Prednisone Survival times in months for two groups - YOUR NAME 5 Two groups of chronic hepatitis patients 04:50 Tuesday, September 27, 2005 Proc lifetest plots and tests The LIFETEST Procedure Testing Homogeneity of Survival Curves for months over Strata Rank Statistics group Log-Rank Wilcoxon Control 5.3828 204.00 Prednisone -5.3828 -204.00 Covariance Matrix for the Log-Rank Statistics group Control Prednisone Control 6.21776 -6.21776 Prednisone -6.21776 6.21776 Covariance Matrix for the Wilcoxon Statistics group Control Prednisone Control 6359.92 -6359.92 Prednisone -6359.92 6359.92 Test of Equality over Strata Pr > Test Chi-Square DF Chi-Square Log-Rank 4.6599 1 0.0309 Wilcoxon 6.5435 1 0.0105 -2Log(LR) 5.4096 1 0.0200 Survival times in months for two groups - YOUR NAME 6 Two groups of chronic hepatitis patients 04:50 Tuesday, September 27, 2005 Reading the data in an alternative way. The data as SAS sees it: Obs group zz xx months status 1 Prednisone 2 2 2 0 2 Prednisone 6 6 6 0 3 Prednisone 12 12 12 0 4 Prednisone 54 54 54 0 5 Prednisone -56 -56 56 1 6 Prednisone 68 68 68 0 7 Prednisone 89 89 89 0 8 Prednisone 96 96 96 0 9 Prednisone 96 96 96 0 10 Prednisone -125 -125 125 1 11 Prednisone -128 -128 128 1 12 Prednisone -131 -131 131 1 13 Prednisone -140 -140 140 1 14 Prednisone -141 -141 141 1 15 Prednisone 143 143 143 0 16 Prednisone -145 -145 145 1 17 Prednisone 146 146 146 0 18 Prednisone -148 -148 148 1 19 Prednisone -162 -162 162 1 20 Prednisone 168 168 168 0 21 Prednisone -173 -173 173 1 22 Prednisone -181 -181 181 1 23 Control 2 2 2 0 24 Control 3 3 3 0 25 Control 4 4 4 0 26 Control 7 7 7 0 27 Control 10 10 10 0 28 Control 22 22 22 0 29 Control 28 28 28 0 30 Control 29 29 29 0 31 Control 32 32 32 0 32 Control 37 37 37 0 33 Control 40 40 40 0 34 Control 41 41 41 0 35 Control 54 54 54 0 36 Control 61 61 61 0 37 Control 63 63 63 0 38 Control 71 71 71 0 39 Control -127 -127 127 1 40 Control -140 -140 140 1 41 Control -146 -146 146 1 42 Control -158 -158 158 1 43 Control -167 -167 167 1 44 Control -182 -182 182 1 Survival times in months for two groups - YOUR NAME 7 Two groups of chronic hepatitis patients 04:50 Tuesday, September 27, 2005 Reading the data in an alternative way. The data as SAS sees it: The LIFETEST Procedure Summary of the Number of Censored and Uncensored Values Percent Stratum group Total Failed Censored Censored 1 Control 22 16 6 27.27 2 Prednisone 22 11 11 50.00 ----------------------------------------------------------------- Total 44 27 17 38.64 Survival times in months for two groups - YOUR NAME 8 Two groups of chronic hepatitis patients 04:50 Tuesday, September 27, 2005 Reading the data in an alternative way. The data as SAS sees it: The LIFETEST Procedure Testing Homogeneity of Survival Curves for months over Strata Rank Statistics group Log-Rank Wilcoxon Control 5.3828 204.00 Prednisone -5.3828 -204.00 Covariance Matrix for the Log-Rank Statistics group Control Prednisone Control 6.21776 -6.21776 Prednisone -6.21776 6.21776 Covariance Matrix for the Wilcoxon Statistics group Control Prednisone Control 6359.92 -6359.92 Prednisone -6359.92 6359.92 Test of Equality over Strata Pr > Test Chi-Square DF Chi-Square Log-Rank 4.6599 1 0.0309 Wilcoxon 6.5435 1 0.0105 -2Log(LR) 5.4096 1 0.0200